Wall Street brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings of $1.75 per share for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.95 and the lowest estimate coming in at $1.66. Alexion Pharmaceuticals posted earnings per share of $1.44 in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.5%. The company is expected to report its next earnings results before the market opens on Wednesday, October 24th.

On average, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $7.23 per share for the current fiscal year, with EPS estimates ranging from $7.05 to $7.52. For the next year, analysts forecast that the business will post earnings of $8.54 per share, with EPS estimates ranging from $8.00 to $9.35. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.58. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.56 EPS.

A number of research analysts recently commented on the company. Credit Suisse Group set a $156.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 15th. Morgan Stanley upped their price objective on Alexion Pharmaceuticals from $157.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. BidaskClub downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 5th. Finally, ValuEngine downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $160.74.

ALXN traded down $0.67 during trading on Monday, reaching $125.89. 1,166,815 shares of the company were exchanged, compared to its average volume of 1,880,347. The company has a market cap of $28.21 billion, a P/E ratio of 24.40, a PEG ratio of 1.15 and a beta of 0.79. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.72 and a quick ratio of 2.27. Alexion Pharmaceuticals has a 52 week low of $102.10 and a 52 week high of $142.24.

A number of hedge funds have recently made changes to their positions in ALXN. Financial Gravity Wealth Inc. acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth $211,000. Dimensional Fund Advisors LP boosted its position in Alexion Pharmaceuticals by 3.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 384,441 shares of the biopharmaceutical company’s stock worth $42,850,000 after acquiring an additional 12,402 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Alexion Pharmaceuticals by 25.5% in the first quarter. Russell Investments Group Ltd. now owns 36,830 shares of the biopharmaceutical company’s stock valued at $4,082,000 after buying an additional 7,476 shares during the period. LPL Financial LLC lifted its holdings in shares of Alexion Pharmaceuticals by 23.4% in the first quarter. LPL Financial LLC now owns 27,709 shares of the biopharmaceutical company’s stock valued at $3,088,000 after buying an additional 5,260 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Alexion Pharmaceuticals by 100.3% in the first quarter. Cubist Systematic Strategies LLC now owns 5,879 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 2,944 shares during the period. Institutional investors own 93.17% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: Why do companies issue stock splits?

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.